Indonesia approves Sinopharm Covid-19 vaccine for emergency use
No detailed efficacy data of Sinopharm's vaccine has been publicly released, but its developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), said the vaccine was 79.34% effective in preventing people from developing the disease, based on interim data
A nurse holds a syringe containing a coronavirus disease (Covid-19) vaccine made by the Beijing Institute of Biological Products, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), at a vaccination center during a government-organized visit, in Beijing, China, April 15, 2021. REUTERS/Thomas Peter
Indonesia's drug regulator on Friday approved a Covid-19 vaccine produced by China's Sinopharm, which is due to be used in a private vaccination scheme under which companies can buy government-procured vaccines to inoculate their staff.
No detailed efficacy data of Sinopharm's vaccine has been publicly released, but its developer, Beijing Biological Products Institute, a unit of Sinopharm subsidiary China National Biotec Group (CNBG), said the vaccine was 79.34% effective in preventing people from developing the disease, based on interim data.
Keep updated, follow The Business Standard's Google news channel
